Biogen Denies Misleading Investors Over Alzheimer's Drug
By Elliot Weld ( July 28, 2022, 9:26 PM EDT) -- Healthcare giant Biogen denied making any misleading statements to its investors Wednesday in a motion to dismiss a securities class action alleging the company knew an Alzheimer's drug was deficient but went ahead with its production anyway....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.